Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement.
Gennady BratslavskyNeil MendhirattaMichael DaneshvarJames BrugarolasMark W. BallAdam MetwalliKatherine L NathansonPhillip M PierorazioRonald S BorisEric A SingerMaria I CarloMary B DalyElizabeth P HenskeColette HyattLindsay MiddletonGloria MorrisAnhyo JeongVivek NarayanW Kimryn RathmellUlka N VaishampayanBruce H LeeDena BattleMichael J HallKhaled HafezMichael A S JewettChristina KaramboulasSumanta Kumar PalA Ari HakimiAlexander KutikovOthon IliopoulosW Marston LinehanEric JonaschRamaprasad SrinivasanBrian M ShuchPublished in: Cancer (2021)
The contribution of germline genetics to the development of renal cell carcinoma (RCC) has long been recognized. However, there is a paucity of guidelines to define how and when genetic risk assessment should be performed for patients with known or suspected hereditary RCC. Without guidelines, clinicians struggle to define who requires further evaluation, when risk assessment or testing should be done, which genes should be considered, and how counseling and/or testing should be performed. To this end, a multidisciplinary panel of national experts was convened to gauge current opinion on genetic risk assessment in RCC and to enumerate a set of recommendations to guide clinicians when evaluating individuals with suspected hereditary kidney cancer.